CRISPR-TB Benchtop Assay

Next-Generation Tuberculosis Detection with CRISPR Technology

Introducing IntelliGenome’s CRISPR-TB Benchtop Blood Assay*—a groundbreaking molecular diagnostic solution for tuberculosis (TB). Designed for CLIA-certified laboratories, this high-throughput, ultra-sensitive assay delivers rapid, accurate, and cost-effective detection of Mycobacterium tuberculosis (Mtb) DNA in plasma or serum. Unlike traditional sputum-based tests, our blood-based approach streamlines TB diagnosis for all patient groups, including pediatric, geriatric, and critically ill populations, where sample collection can be challenging.

Developed in collaboration with Professor Tony Hu’s research team at Tulane University, this innovative test harnesses CRISPR technologyto precisely detect Mtb cell-free DNA (cfDNA) in blood. With unmatched sensitivity, our advanced molecular platform enables early and reliable TB diagnosis, revolutionizing the way tuberculosis is detected and managed.

Why Choose CRISPR-TB?

Unmatched Sensitivity & Accuracy

Faster, Simpler, and More Accessible Testing

Our assay directly detects low-abundance Mtb cfDNA in human blood, ensuring high precision and early disease identification—especially in cases where traditional methods fall short.

Faster, Simpler, and More Accessible Testing

By eliminating the need for sputum collection, CRISPR-TB significantly improves access to TB diagnostics for vulnerable groups, including children, elderly, and critically ill patients who may struggle with sample collection.

Scalable and Cost-Effective

FDA Breakthrough Designation

Designed for CLIA-certified laboratories, our benchtop system supports high-throughput testing, making it a cost-effective solution for public health screening and clinical diagnostics.

FDA Breakthrough Designation

The FDA’s recognition underscores CRISPR-TB’s potential to revolutionize TB care. As the first CRISPR-based blood test for Mtb, it addresses critical gapsin diagnosing hard-to-reach populations and complex extra-pulmonary TB (EPTB) cases, accelerating treatment initiation and reducing transmission.

Learn More: CRISPR-TB Blood Test Receives FDA Breakthrough Device Designation

CRISPR-TB Benchtop Assay

Next-Generation Tuberculosis Detection with CRISPR Technology

Why Choose CRISPR-TB?

Unmatched Sensitivity & Accuracy

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Scalable and Cost-Effective

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

Be Part of the Future of TB Diagnostics

Transforming the TB Testing Landscape

CRISPR-TB Benchtop Assay

Next-Generation Tuberculosis Detection with CRISPR Technology

Why Choose CRISPR-TB?

Unmatched Sensitivity & Accuracy

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Faster, Simpler, and More Accessible Testing

Scalable and Cost-Effective

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

FDA Breakthrough Designation

Be Part of the Future of TB Diagnostics

Transforming the TB Testing Landscape

This website uses cookies.